Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Cancer Vaccines. Found 7 abstracts

Geynisman DM, Chien CR, Smieliauskas F, Shen C, Shih YC. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014 Jan;10(11):3415-24.   PMCID: PMC4514043
Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006 Jul;24(19):3107-12.
Coukos G, Courreges MC, Benencia F. Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm. Curr Gene Ther. 2003 Apr;3(2):113-25.
Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res. 2003 Apr;9(4):1517-27.
Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002 Feb;29(1 Suppl 1):32-42.
Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001 Oct;7(10):3012-24.
von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 2001 May;7(5):1181-91.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Cancer Vaccines

Cancer Vaccines Human Female Male immunology Non-US Gov't Support methods therapeutic use drug therapy therapy Aged Immunotherapy metabolism Cytokines Neoplasms US Gov't Support-PHS Treatment Outcome Adult T-Lymphocytes Membrane Glycoproteins Ovarian Neoplasms Dendritic Cells drug effects Gene Therapy Immunologic Adjuvants adverse effects Interferon Type II Middle Age Middle Aged genetics Skin Enzyme-Linked Immunosorbent Assay Immunity Immunoglobulin Idiotypes Synthetic Vaccines Headache Neoplasm Proteins cytology Biopsy Survival Analysis Combined Modality Therapy CD4-Positive T-Lymphocytes Th1 Cells adverse Amino Acid Sequence Biological Therapy CD40 Ligand Molecular Sequence Data Monoclonal Antibodies Cell Division Antibody Formation Cell Death Lymph Nodes effects Inflammation virology Cohort Studies MHC Class I Genes Neoplasm Drug Resistance Antineoplastic Agents Phenotype Granulocyte-Macrophage Colony-Stimulating Factor Apoptosis Phagocytosis Ultraviolet Rays Cost-Benefit Analysis Hemocyanin Skin Tests Antineoplastic Combined Chemotherapy Protocols Skin Diseases Cytotoxic T-Lymphocytes Delayed Hypersensitivity Glandular and Epithelial Neoplasms Tetanus Toxoid Peritoneal Neoplasms Peptide Fragments secretion Cell Line pathology Neoplasm Staging administration & dosage Mice Saponins Mononuclear Leukocytes prevention & control HLA-A2 Antigen Cellular Immunity Flow Cytometry Pain Non-Hodgkin Lymphoma Simplexvirus Tumor Cell Line Mutation Carrier Proteins Adjuvant Chemotherapy Follow-Up Studies Time Factors economics chemically induced Melanoma T-Lymphocyte Epitopes
Last updated on Wednesday, February 05, 2020